Illumina, Inc. / Pacific Biosciences of California, Inc. merger inquiry

Competition Markets Authority

January 6
12:59 2020

Phase 2

Administrative timetable

Date of referral: 27 June 2019

Statutory deadline: 5 February 2020


Merger abandoned

3 January 2020: Illumina has abandoned its anticipated takeover of PacBio after an in-depth CMA merger probe highlighted serious competition concerns.

Illuminas response to the CMAs remedies working paper

Parties Response to Provisional Findings

Notice of extension of inquiry period

The Inquiry Group has decided to extend the reference period by 8 weeks under section 39(3) of the Enterprise Act 2002. The Inquiry Group aims to complete the inquiry as soon as possible and in advance of this date.

Third party response to notice of possible remedies and provisional findings

Parties response to notice of possible remedies

Provisional Findings

24 October 2019: The CMA has provisionally found competition concerns as part of its in-depth investigation of the anticipated acquisition between Illumina and PacBio.

Third party submissions

Issues statement

1 August 2019: The issues statement sets out the scope of the inquiry. It outlines initial theories on what might be adversely affecting competition, but it does not set out findings or conclusions. The deadline for submissions on the issues statement is 5pm, Thursday 15 August 2019.

Merger notice

Response to phase 1 decision

Inquiry group appointed

27 June 2019: The CMA has appointed the inquiry group:

Stuart McIntosh (Chair), Humphrey Battcock, Colleen Keck and

Related Articles


  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:

Post my comment

Recent Comments

Follow Us on Twitter

Share This

Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: